Medigene AG: Adjustment of EBITDA guidance for fiscal year 2019 after receiving the assessment results from FREP

ID: 1555511
recent pressrelease next pressrelease

(businesspress24) - Public disclosure of inside information according to article 17 MAR

Martinsried/Munich (28.01.2020/18:25) - 28 January 2020. The Executive Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard) today decided to adjust its previous 2019 full-year guidance on EBITDA loss.

In relation with the sale of Veregen®, which took place in April 2019, the inventories of the active pharmaceutical ingredient were revalued by EUR 4.7 million in the "Inventories". This cash neutral loss which was previously taken into account in 2019 will now be accounted for retroactively in the fiscal year 2018 after receiving the assessment result from the German Financial Reporting Enforcement Panel (FREP). As a result of this, and due to available preliminary EBITDA results, the Executive Board is reducing the forecast of the EBITDA loss for the 2019 financial year from the previously reported EUR -23 to -28 million to an anticipated EUR -17 to -18 million. The EBITDA loss for the 2018 financial year retroactively increases from the original EUR -16.3 million to EUR -20.9 million.

These adjustments are cash neutral, i.e. Medigene''s financial resources remain unaffected.

(end)

emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg/Martinsried
country: Germany
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
e-mail: investor(at)medigene.com
website: www.medigene.de

ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate




More information:
https://cryptoonfire.com http://sixfsa.crucialconstructs.com/ https://healthessential101.com/maxi-climber-reviews/



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:

Die Medigene AG ist ein börsennotiertes Biotechnologie-Unternehmen mit Hauptsitz in Martinsried bei München.



PressContact / Agency:



published by: irw
print pressrelease  send to a friend  

Date: 01/28/2020 - 12:46
Language: English
News-ID 1555511
Character count: 2698
Kontakt-Informationen:
Firma: Medigene AG
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Wien
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 526

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 182


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.